Back to Authors

Yue, Mei

A5113551046 | I4210146710

Mayo Clinic

Mayo Clinic in Florida

Citations 18

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis

Science Translational Medicine | March 29, 2017 | Volume: 9 | Issue: 383 | Pages: No page available

10.1126/scitranslmed.aai7866 | PMID 28356511

Poly(GP) proteins are a promising pharmacodynamic marker for developing and testing therapeutics for treating C9ORF72 -associated amyotrophic lateral sclerosis.
TIMP-1 Attenuates Blood–Brain Barrier Permeability in Mice with Acute Liver Failure

Journal of Cerebral Blood Flow & Metabolism | March 27, 2013 | Volume: 33 | Issue: 7 | Pages: 1041-1049

10.1038/jcbfm.2013.45 | PMID 23532086

Blood-brain barrier (BBB) dysfunction in acute liver failure (ALF) results in increased BBB permeability that often precludes the patients from obtaining a life-saving liver transplantation. It remains controversial whether matrix metalloproteinase-9 (MMP-9) from the injured liver contributes to the deregulation of BBB function in ALF. We selectively upregulated a physiologic inhibitor of MMP-9 (TIMP-1) with a single intracerebroventricular injection of TIMP-1 cDNA plasmids at 48 and 72 hours, or with pegylated-TIMP-1 protein. Acute liver failure was induced with tumor necrosis factor-α and D-(+)-galactosamine in mice. Permeability of BBB was assessed with sodium fluorescein (NaF) extravasation. We found a significant increase in TIMP-1 within the central nervous system (CNS) after the administration of TIMP-1 cDNA plasmids and that increased TIMP-1 within the CNS resulted in an attenuation of BBB permeability, a reduction in activation of epidermal growth factor receptor and p38 mitogen-activated protein kinase signals, and a restoration of the tight junction protein occludin in mice with experimental ALF. Pegylated TIMP-1 provided similar protection against BBB permeability in mice with ALF. Our results provided a proof of principle that MMP-9 contributes to the BBB dysfunction in ALF and suggests a potential therapeutic role of TIMP-1 in ALF.
O4‐06–02: Reversible dendritic spine degeneration and compensatory filopodial extension in a conditional mutant tauopathy model

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2008.05.546

P1–002: Synaptic degeneration and memory loss in a model of tauopathy

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_4 | Pages: No page available

10.1016/j.jalz.2006.05.377

O4–05–01: Methods of cell death and recovery in the rTg4510 and iP301L inducible mouse models of tauopathy

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2006.05.327

P1–087: Identification of toxic tau species

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_4 | Pages: No page available

10.1016/j.jalz.2006.05.462

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice

Proceedings of the National Academy of Sciences | June 12, 2006 | Volume: 103 | Issue: 25 | Pages: 9673-9678

10.1073/pnas.0602913103 | PMID 16769887

An orally bioavailable and blood–brain barrier penetrating analog of the kinase inhibitor K252a was able to prevent the typical motor deficits in the tau (P301L) transgenic mouse model (JNPL3) and markedly reduce soluble aggregated hyperphosphorylated tau. However, neurofibrillary tangle counts were not reduced in the successfully treated cohort, suggesting that the main cytotoxic effects of tau are not exerted by neurofibrillary tangles but by lower molecular mass aggregates of tau. Our findings strongly suggest that abnormal tau hyperphosphorylation plays a critical role in the development of tauopathy and suggest a previously undescribed treatment strategy for neurodegenerative diseases involving tau pathology.
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

Science | July 14, 2005 | Volume: 309 | Issue: 5733 | Pages: 476-481

10.1126/science.1113694 | PMID 16020737

Neurofibrillary tangles (NFTs) are the most common intraneuronal inclusion in the brains of patients with neurodegenerative diseases and have been implicated in mediating neuronal death and cognitive deficits. Here, we found that mice expressing a repressible human tau variant developed progressive age-related NFTs, neuronal loss, and behavioral impairments. After the suppression of transgenic tau, memory function recovered, and neuron numbers stabilized, but to our surprise, NFTs continued to accumulate. Thus, NFTs are not sufficient to cause cognitive decline or neuronal death in this model of tauopathy.